Lianhua Qingwen's Road to Internationalization is Getting Wider and Wider

According to the announcement issued by the R&D and manufacturer of Lianhua Qingwen, Yiling Pharmaceutical, as of now, Lianhua Qingwen Capsules have been registered and listed in nearly 30 countries and regions around the world, covering Canada, Russia, the Philippines, Kuwait and other countries. played an important role in epidemic prevention and control.

In addition to China, Lianhua Qingwen has also been approved for new crown indications in Kuwait, Mongolia and other countries; in Uzbekistan, Lianhua Qingwen has been selected into the white list of anti-epidemic drugs issued by the Ministry of Health; In Thailand, Cambodia, Indonesia and other countries, even Hua Qingwen was allowed to enter the designated hospital for COVID-19 to treat local patients.

At the same time as the registered territory continues to expand, Lianhua Qingwen, as an important foreign aid material, followed batches of expert teams to the front line of the fight against the epidemic.

Since the outbreak, Yiling Pharmaceutical has donated more than one million boxes of Lianhua Qingwen to Italy, Iraq, Indonesia, Ecuador, the SCO Secretariat and other countries and international organizations, and has cooperated with the United States, Canada, Thailand, Peru and other countries.

More than 20 countries and regions including more than 20 countries and regions have held dozens of remote academic exchange conferences to share the experience of Chinese medicine in anti-epidemic to the world.

The blooming of Lianhua Qingwen overseas is the epitome of the recognition of traditional Chinese medicine in the world. And all of this is inseparable from the support of research evidence.

Lianhua Qingwen Capsule won the second prize of National Science and Technology Progress Award in 2011. Lianhua Qingwen is also a big compound Chinese patent medicine for the treatment of influenza that has entered the US FDA clinical research.

At present, the US FDA Phase II clinical cases of Lianhua Qingwen Capsules have been enrolled and are in the stage of data analysis and statistics.

Since the outbreak of COVID-19, many experts at home and abroad have carried out basic and clinical research on Lianhua Qingwen's prevention and treatment of COVID-19, providing Chinese medicine wisdom for epidemic prevention and control in China and the world.

In March 2020, Professor Yang Zifeng's research group from the State Key Laboratory of Respiratory Diseases published a paper titled "Lianhua Qingwen has antiviral and anti-inflammatory effects on novel coronavirus" in the mainstream journal "Pharmacological Research" in the pharmacology field, confirming that Lianhua Qingwen has antiviral and anti-inflammatory effects on the new coronavirus.

Qingwen exerts its anti-new coronavirus activity by inhibiting virus replication and inhibiting the expression of inflammatory factors in host cells, which provides an experimental basis for the application of Lianhua Qingwen in the treatment of new coronary pneumonia.

With the participation of a number of academicians and 23 hospitals for the treatment of new coronary pneumonia, the "Chinese Medicine Lianhua Qingwen Capsules in the treatment of new coronavirus pneumonia" was published in the European authoritative journal "Plant Medicine" in May 2020.

Prospective, randomized, controlled, multi-center.

The results of the "Clinical Study" show that combined application of Lianhua Qingwen Capsules orally for 14 days on the basis of conventional treatment can improve the improvement rate of clinical symptoms such as fever, fatigue, and cough of new coronary pneumonia, and curb the deterioration of new coronary pneumonia.

In January 2021, Prof. Wu Caisheng from the School of Pharmacy of Xiamen University and Prof. Chai Yifeng's team from Naval Medical University made new progress in the research on the pharmacological active ingredients and mechanism of Lianhua Qingwen Capsules in the prevention and treatment of new coronary pneumonia.

The Anti-New Coronary Pneumonia Pharmacological Active Components of Traditional Chinese Medicine Lianhua Qingwen Capsule" was published in the top pharmacy journal "Journal of Pharmacy".

This study confirms that Lianhua Qingwen may inhibit the new coronavirus by effectively affecting the binding between ACE2 and S protein, and provides an experimental basis for the prevention and treatment of new coronary pneumonia by Lianhua Qingwen Capsules.

An extension of research and clinical evidence. The latest research also found that Lianhua Qingwen showed stable in vitro antiviral effects on mutants such as Alpha, Beta, and Delta.